HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccine-mediated T-cell responses.

Abstract
Blockade of CTLA-4 by monoclonal antibodies (mAb) can mediate regression of tumors and increase the efficacy of tumor antigen specific vaccines. Blockade of CTLA-4 has also been shown to significantly increase the avidity of antigen-specific T cells after immunization with live recombinant viral vector based vaccine. Here, we demonstrate a biological synergy between CTLA-4 blockade and active vaccine therapy consisting of recombinant vaccinia and avipox viruses expressing carcinoembryonic antigen (CEA) and three T cell costimulatory molecules to enhance antitumor effects. However, this synergy was very much dependent on the temporal relationship of scheduling of the two agents. We evaluated the strategies in both a foreign antigen model using beta-galactosidase as immunogen, and in a "self" antigen model using CEA as immunogen. For antitumor activity the model used consisted of mice transgenic for human CEA and a murine carcinoma cell line transfected with CEA. The enhanced antitumor activity after vaccine and CTLA-4 blockade did not result in any signs of autoimmunity. These studies form a rational basis for the use of vector-based vaccines with anti-CTLA-4 and demonstrate that both enhancement of positive costimulatory signals and inhibition of negative costimulatory signals can be simultaneously exploited. These studies also underscore the importance of "drug" scheduling in vaccine combination therapies.
AuthorsMala Chakraborty, Jeffrey Schlom, James W Hodge
JournalCancer immunology, immunotherapy : CII (Cancer Immunol Immunother) Vol. 56 Issue 9 Pg. 1471-84 (Sep 2007) ISSN: 0340-7004 [Print] Germany
PMID17318654 (Publication Type: Journal Article, Research Support, N.I.H., Intramural)
Chemical References
  • Antibodies, Monoclonal
  • Antigens, CD
  • Antigens, Differentiation
  • CTLA-4 Antigen
  • CTLA4 protein, human
  • Cancer Vaccines
  • Ctla4 protein, mouse
  • Recombinant Proteins
Topics
  • Animals
  • Antibodies, Monoclonal (pharmacology)
  • Antibody Affinity
  • Antigens, CD (drug effects)
  • Antigens, Differentiation (drug effects)
  • CTLA-4 Antigen
  • Cancer Vaccines (pharmacology)
  • Cell Line, Tumor
  • Drug Synergism
  • Female
  • Humans
  • Immunization (methods)
  • Lymphocyte Activation
  • Mice
  • Mice, Inbred C57BL
  • Neoplasms (immunology, therapy)
  • Recombinant Proteins (genetics)
  • T-Lymphocytes (immunology)
  • Vaccinia virus (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: